|
| Exchange Disseminated Time | Themis Medicare Ltd has informed BSE that the Board of Directors of the Company at its meeting held on January 15, 2014, has approved the following proposals:
1. Conversion of 400000 optionally convertible Preferential warrants of Rs. 10/- each at a premium of Rs. 75/- issued to some of the Indian Promoters into 1 fully paid equity share of Rs. 10 each at a premium of Rs. 75/- per share as per provisions of SEBI (issue of Capital & Disclosure Requirements) Regulations 2009.
2. The Board also noted commencement of supply to Novartis India Limited of Diclofenac Topical Gel using TPM™ Transdermal Drug Delivery System in finished dosage pharmaceutical form as per agreement entered with them on March 26, 2013. |
|
|